Form 4: Upstream Bio CFO Sells Shares for Tax Obligations

Upstream Bio's CFO and COO, Michael Gray, sold 852 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Michael Gray, CFO and COO of Upstream Bio, Inc., reported a transaction involving the company's common stock.
• On March 16, 2026, Gray disposed of 852 shares of Upstream Bio common stock.
• The shares were sold at a price of $9.29 per share.
• This sale was an automatic "sell-to-cover" transaction to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Gray beneficially owns 29,648 shares of Upstream Bio common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, non-discretionary 'sell-to-cover' transaction for tax purposes following RSU vesting, which is a common practice for executive compensation.

Positives

• The underlying event for the sale is the vesting of restricted stock units, which represents a form of executive compensation and a positive for the executive.
• The sale was non-discretionary and solely for tax withholding purposes, not an indication of a lack of confidence in the company.

Negatives

• The executive's direct beneficial ownership of common stock decreased by 852 shares.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a report of a past transaction.

Management Comments

• The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person.
• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are common practice for executives receiving equity compensation, particularly restricted stock units, and are generally not indicative of a change in management's outlook on the company's prospects. This is a standard mechanism to manage tax liabilities upon vesting.

Comparison to Industry Standards

• This 'sell-to-cover' transaction aligns with common industry practices for executive equity compensation and tax management.
• Companies like Pfizer (PFE) and Moderna (MRNA) frequently report similar Form 4 filings where executives sell a portion of vested equity to cover tax obligations, reflecting a standard operational procedure rather than a discretionary investment decision.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a small, non-discretionary sale for tax purposes.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 reports a routine 'sell-to-cover' transaction by a key executive to satisfy tax obligations upon RSU vesting. Such non-discretionary sales are common and do not typically signal a change in the company's fundamentals or management's confidence. Therefore, it does not warrant a change in investment recommendation.

Keywords

Upstream Bio, UPB, Form 4, Insider Trading, Michael Gray, CFO, COO, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Beneficial Ownership